Dr Sebastian Remberg


Sebastian advises private equity funds and other financial sponsors as well as public and private corporates on the full range of M&A and corporate transactions including buyouts, exits, mergers, carve-outs, reorganisations, joint ventures, co-investments as well as consortium and shareholder arrangements. 
Sebastian has a particular expertise in the healthcare / life science sector. He spent some time as a secondee at the legal M&A department of a leading global life science Company.


Representative matters

BC Partners on the acquisition of Tentamus Group GmbH from Auctus.

Partners Group and CVC as a bidding consortium on the intended acquisition of CeramTec Group from BC Partners.

Bridgepoint on the acquisition of a majority stake in the PTV Group, a leading global software company for traffic simulation and planning and a provider of optimization solutions for transport logistics from ultimate owner Porsche SE.

A global pharmaceutical and healthcare company on the sale of its men’s health product Nebido™ (testosterone undecanoate) to Grünenthal.

Published Work

  • Sebastian Remberg (2012), "Das Rechtsmissbrauchsverbot als Minderheitenschutz im Gesellschaftsrecht; dargestellt am Beispiel des aktienrechtlichen Squeeze-out", Dissertation
  • Sebastian Remberg (2008), "Recht auf Verteidigung und effektiven Rechtsschutz gegen Vermögensbeschlagnahme wegen Terrorismusverdacht durch Ratsbeschluss", European Law Reporter 2008, 60-67



Admitted as German Rechtsanwalt, Germany, 2013


Second German Law Degree, 2013

Dr. iur., University of Freiburg, Germany, 2012

LL.M. University of Queensland, Australia, 2008

First German Law Degree, 2007

A&O Shearman was formed on May 1, 2024 by the combination of Shearman & Sterling LLP and Allen & Overy LLP and their respective affiliates (the legacy firms). Any matters referred to above may include matters undertaken by one or more of the legacy firms rather than A&O Shearman.